|
InterceptCS PROGRESS REPORT
May 25, 2006
Burlington, Ontario
THE JENEX CORPORATION (“Jenex” or the “Corporation”) (TSX Venture Exchange – JEN). The Corporation launched their interceptCS™ Cold Sore Prevention System in Canada in April/2006. The interceptCS Cold Sore Prevention System was featured in back- to-back national flyers in April with Canada’s largest drug store chain. The flyer weeks were also supported by the playing of the interceptCS radio commercial on their in-store radio system. The interceptCS radio commercials are now being aired on radio stations in all major markets across Canada. Michael Mayo, Director of Marketing and Sales states, “We are pleased with our initial sales results and optimistic about our ability to secure an increasing market share of the cold sore category. Our immediate task is to inform and educate the public about interceptCS and its unique prevention capability. Testimonials are arriving from new customers telling us about their experience and satisfaction with the interceptCS Cold Sore Prevention System.”
Michael Jenkins, President and CEO states, “We are very pleased with the execution of the interceptCS Canadian launch. Our national distribution is strong with product in stores in all provinces and territories in the country. The sales trends and consumer feedback is positive.”
Additionally, Jenex reports it has received worldwide patent pending status for the interceptCS Cold Sore Prevention System and has secured trademark registration for key markets for interceptCS.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy technology. interceptCS is the first product clinically proven to prevent cold sores. Jenex has been approved to market interceptCS in Canada with the claim “For prevention and relief of the symptoms of herpes labialis (cold sores) such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks”. More information about the Corporation can be found at www.JenexCorp.com & www.interceptCS.com
Enquiries:
Michael A. Jenkins, President
The Jenex Corporation
940 Sheldon Court, Suite 207
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
|
